Neurogene Inc. Stockholders Equity

• Neurogene Inc. showed a decrease of -14.7% in Stockholders Equity from 2024 to 2025.
• This data is from Neurogene Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2026.
• XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $136.94 million | Q2 2017: $124.61 million | Q3 2017: $114.09 million | Q1 2018: $85.83 million | Q2 2018: $90.68 million | Q3 2018: $76.72 million | Q1 2019: $71.54 million | Q2 2019: $72.33 million | Q3 2019: $66.88 million | Q1 2020: $137.12 million | Q2 2020: $128.70 million | Q3 2020: $200.34 million | Q1 2021: $178.97 million | Q2 2021: $167.07 million | Q3 2021: $154.87 million | Q1 2022: $130.09 million | Q2 2022: $116.71 million | Q3 2022: $105.65 million | Q1 2023: -$157.60 million | Q2 2023: -$169.05 million | Q3 2023: -$183.21 million | Q1 2024: $170.78 million | Q2 2024: $155.01 million | Q3 2024: $137.41 million | Q1 2025: $291.80 million | Q2 2025: $273.26 million | Q3 2025: $265.54 million.
• Over the full 16 years of available data (2011 to 2025), Neurogene Inc.'s Stockholders Equity has grown by 773.8%.
• Historical annual values: Fiscal year 2025: $264.89 million | Fiscal year 2024: $310.38 million | Fiscal year 2023: $186.02 million | Fiscal year 2022: -$145.74 million | Fiscal year 2021: -$91.88 million | Fiscal year 2020: $191.22 million | Fiscal year 2019: $141.69 million | Fiscal year 2018: $72.67 million | Fiscal year 2017: $98.89 million | Fiscal year 2016: $144.66 million | Fiscal year 2015: $108.42 million | Fiscal year 2014: $36.15 million | Fiscal year 2014: -$65.39 million | Fiscal year 2013: -$65.69 million | Fiscal year 2012: -$51.10 million | Fiscal year 2011: -$39.31 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026